Medical/Pharmaceuticals
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 767762...
2025-06-12 21:17
1698
Turning Partnerships into Global Healthcare Solutions with VARON Oxygen Solutions
NEW YORK, June 12, 2025 /PRNewswire/ -- In hospitals, senior living centers,
and clinics around the globe, lives are being improved every day by a quiet but
powerful force in respiratory care: VARON Oxygen Solutions.
2025-06-12 20:50
1448
Gene Solutions and Topgen Join Forces to Advance Precision Oncology All Over China
SHANGHAI, June 12, 2025 /PRNewswire/ -- Gene Solutions
2025-06-12 20:14
2404
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases
CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced a license agreement with Visterra, Inc. to advance Visterra's next-generation biotherapeutic pipeline for immune-mediated ...
2025-06-12 20:03
1814
Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing
* 1st production of pharmaceutical grade egg and milk challenge meals * Product portfolio of challenge meals now includes peanut, milk and egg * Innovation pipeline includes development of 'Top 9' allergen products as well as a products suitable from 6 months DEESIDE, Wales, June 12, 2025 /P...
2025-06-12 19:06
1779
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
* Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% * DZD8586 exhibited significant antitumor activity in heavily pretreated chronic l...
2025-06-12 18:13
1778
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking placeJune 16-19 in Boston Convention & Exhibition Cen...
2025-06-12 15:39
1794
Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
* 66% of patients surveyed in APAC are experiencing delays in seeing specialist doctor, with an average waiting time of 47 days * 89% of healthcare professionals believe that AI and predictive analytics can save lives by facilitating earlier interventions * Building trust among patients and ...
2025-06-12 12:00
1817
Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand
HONG KONG and SHANGHAI, June 11, 2025 /PRNewswire/ -- The Ping An Good Doctor Brand Revamp & Ping An Healthcare Services Brand Launch Conference was held in Shanghai. Ping An Healthcare and Technology Company Limited ("the Company", Stock Code: 1833.HK) officially revamped its brand to "Ping An Go...
2025-06-11 19:32
5160
Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025
TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking placeJune 16–19 in Boston, MA. The c...
2025-06-11 15:58
1887
MGI Tech Partners with Asia Pathogen Genomics Initiative to Advance Pathogen Genomics for Public Health in Asia
SINGAPORE, June 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Asia Pathogen Genomics Initiative ("Asia PGI"), part of the Duke-NUS Centre for Outbreak Preparedness (COP), have recently...
2025-06-11 14:36
2208
Fosun International Receives the "ESG & Sustainability Award" and Two Other Prestigious Honors from Global Banking and Finance Review
HONG KONG, June 11, 2025 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) was recently notified by the renowned British finance magazine,Global Banking and Finance Review, that it has received three awards: "ESG & Sustainability Awards – Best Sustainable Development Company As...
2025-06-11 14:04
4085
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- ...
2025-06-11 12:00
2248
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱® ) was...
2025-06-11 11:34
2186
Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy we...
2025-06-10 23:52
2990
Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gat...
2025-06-10 21:22
2236
Ambiq Receives Frost & Sullivan's 2025 Global Company of the Year Award for Its Leadership in Healthcare Semiconductor Solutions
Ambiq recognized for pioneering energy-efficient semiconductor solutions that empower next-generation AI-enabled healthcare innovations SAN ANTONIO, June 10, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce thatAmbiq has been awarded the 2025 Global Company of the Year Award in the s...
2025-06-10 21:00
1676
Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation
CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Insilico Medicine
2025-06-10 21:00
2197
ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
SUZHOU, China, June 10, 2025 /PRNewswire/ -- ImmVira, a global leading clinical-stage biotechnology company focused on the development of next-generation novel oncolytic immunotherapy for treatment of cancer, announced that the first patient diagnosed with NMIBC has been dosed in a multi-regiona...
2025-06-10 20:00
2276
Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
SHANGHAI and NEW YORK, June 10, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leadingShanghai-based high-tech biopharmaceutical company specializing in biologics R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., aNew York-based biotechnology company...
2025-06-10 18:00
1877
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 300 media titles]
2026-01-21 12:39JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 296 media titles]
2026-01-15 10:00Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 279 media titles]
2026-01-20 15:40
